Laboratory Monitoring of Newer Anticoagulants and Fondaparinux

Venous thromboembolism (VTE) includes deep vein thrombosis (DVT) and pulmonary embolism (PE). The estimates of incidence are to the tune of ~2 per 1000 first events every year in the West; it is a major cause of morbidity and mortality. The advent of direct oral anticoagulants (DOACs), such as dabigatran, rivaroxaban, apixaban, and edoxaban, has transformed the management of thromboembolic disorders. These newer medications offer several advantages over traditional vitamin K antagonists (VKAs), including predictable pharmacokinetics, fixed dosing, and less need for routine laboratory monitoring. Consequently, DOACs have become the first-line treatment for conditions like atrial fibrillation, deep vein thrombosis, and pulmonary embolism. Laboratory tests for direct oral anticoagulants (DOACs) are typically unnecessary for regular therapeutic monitoring. However, specific assays can assess their effects: the activated partial thromboplastin time (aPTT) is useful for dabigatran, while anti-Xa assays are preferred for direct factor Xa inhibitors. The thrombin time (TT) can also monitor dabigatran, though it’s less common. No single test is universally accepted for DOACS. Fondaparinux, an indirect FXa inhibitor, is monitored by the chromogenic anti-FXa assay. This chapter explores the clinical applications and mechanisms of Direct Oral Anticoagulants (DOACs) and Fondaparinux, highlighting their significance in patient care. It addresses the necessity of monitoring DOACs, the role of laboratory assessments in managing patients, and the challenges associated with current testing methods. Additionally, it emphasizes recent advancements in DOAC monitoring aimed at optimizing care, reducing adverse events, and supporting personalized anticoagulation therapy.